The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1662
ISSUE1662
October 31, 2022
Two New Oral Testosterone Products for Hypogonadism
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Two New Oral Testosterone Products for Hypogonadism
October 31, 2022 (Issue: 1662)
The FDA has approved two new oral formulations
of testosterone undecanoate — Kyzatrex (Marius)
and Tlando (Antares) — for treatment of males
with a deficiency of endogenous testosterone
due to conditions such as Klinefelter...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.